Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 35
Filter
1.
Int J Gynecol Cancer ; 18(3): 499-505, 2008.
Article in English | MEDLINE | ID: mdl-18476949

ABSTRACT

We conducted study to determine whether and how the expression of the hypoxia-inducible factor 1alpha (HIF-1alpha) gene relates to outcome in patients with epithelial ovarian cancer. A total of 66 patients with epithelial ovarian cancer, who underwent primary surgery followed by platinum-based chemotherapy, were entered into this study. We confirmed the expression of HIF-1alpha and the vascular endothelial growth factor (VEGF) by immunohistochemistry. To determine the quantity of HIF-1alpha and VEGF expression, messenger RNA of each gene was measured by real-time reverse transcription-polymerase chain reaction. The cutoff values were determined by the receiver-operating characteristic curve according to survival. The protein expressions of HIF-1alpha and VEGF were strongly observed in the cancer cells. The cutoff value of HIF-1alpha and VEGF gene expression was 6.0 and 3.0, respectively. The expression of HIF-1alpha did not relate to clinical stage, but tumor with low VEGF expression was observed more frequently in stage I patients. The response rate to chemotherapy did not differ between high and low expression of both genes. The overall survival for patients with high expression of HIF-1alpha was significantly lower, but disease-free survival did not differ between high and low expression of HIF-1alpha, whereas both overall and disease-free survival for patients with high expression of VEGF were significantly lower. Multivariate analysis revealed that FIGO stage and HIF-1alpha expression were independent prognostic factors but that VEGF was not. The present study suggested that the expression level of HIF-1alpha could be an independent prognostic factor in epithelial ovarian cancer.


Subject(s)
Gene Expression Regulation, Neoplastic , Hypoxia-Inducible Factor 1, alpha Subunit/metabolism , Neoplasms, Glandular and Epithelial/genetics , Ovarian Neoplasms/genetics , Vascular Endothelial Growth Factor A/metabolism , Adult , Aged , Biomarkers, Tumor/genetics , Chemotherapy, Adjuvant , Combined Modality Therapy , Confidence Intervals , Female , Humans , Hypoxia-Inducible Factor 1, alpha Subunit/genetics , Immunohistochemistry , Kaplan-Meier Estimate , Middle Aged , Multivariate Analysis , Neoplasm Staging , Neoplasms, Glandular and Epithelial/mortality , Neoplasms, Glandular and Epithelial/pathology , Neoplasms, Glandular and Epithelial/therapy , Ovarian Neoplasms/mortality , Ovarian Neoplasms/pathology , Ovarian Neoplasms/therapy , Ovariectomy/methods , Probability , Prognosis , Proportional Hazards Models , Prospective Studies , Reverse Transcriptase Polymerase Chain Reaction , Survival Rate , Treatment Outcome , Vascular Endothelial Growth Factor A/genetics
2.
Int J Gynecol Cancer ; 17(5): 1040-6, 2007.
Article in English | MEDLINE | ID: mdl-17433067

ABSTRACT

Our previous findings suggested that lower cell proliferation of clear cell carcinoma (CCC) of the ovary may contribute to its resistance to chemotherapy. We conducted the present study to find the gene that regulates cell proliferation of CCC and to elucidate whether it contributes to cisplatin (CDDP) resistance. Complementary DNA microarray analysis revealed that the gene expression level of galectin-3 of CCC cell lines (KK, RMG-I, HAC-2) was over threefold higher than that of ovarian serous adenocarcinoma (SAC) cell lines (HRA, KF). S-phase fraction increased after knocking down galectin-3 using small interfering RNA in RMG-I, KK, and HAC-2 cells. The protein expression of p27 decreased after knocking down galectin-3. CDDP-induced apoptosis was increased after knocking down galectin-3, and this cytotoxic effect was canceled by roscovitine. Immunohistochemical staining showed that galectin-3 expression in tumors of 20 CCC was significantly more frequent than that of 20 SAC (70.0% vs 15.0%, P = 0.0004). The present study showed that the expression of galectin-3 in CCC might contribute to its lower cell proliferation and lead to CDDP resistance.


Subject(s)
Adenocarcinoma, Clear Cell/metabolism , Drug Resistance, Neoplasm/genetics , Galectin 3/physiology , Ovarian Neoplasms/metabolism , Adenocarcinoma, Clear Cell/chemistry , Adenocarcinoma, Clear Cell/drug therapy , Antineoplastic Agents/therapeutic use , Apoptosis , Cell Line, Tumor , Cisplatin/therapeutic use , Cyclin-Dependent Kinase Inhibitor p27/genetics , Cyclin-Dependent Kinase Inhibitor p27/metabolism , Female , Galectin 3/analysis , Galectin 3/genetics , Humans , Immunohistochemistry , Ovarian Neoplasms/chemistry , Ovarian Neoplasms/drug therapy , RNA, Small Interfering/pharmacology
3.
Int J Gynecol Cancer ; 17(1): 76-82, 2007.
Article in English | MEDLINE | ID: mdl-17291235

ABSTRACT

We conducted the present study to investigate whether and how chemosensitivity can be determined by means of genetic diagnosis using drug-resistance genes in patients with epithelial ovarian cancer. A total of 75 patients who had epithelial ovarian cancer with measurable lesions were entered into this study. Thirty-three patients received first-line chemotherapy, consisting of paclitaxel and carboplatin (TJ). Forty-two patients received second-line chemotherapy, 22 received EP therapy consisting of etoposide and cisplatin (CDDP), and 20 received irinotecan (CPT-11) and CDDP (CPT-11/CDDP) therapy. Tumor samples were obtained before chemotherapy. MessengerRNA expressions of the multidrug-resistance (MDR)-1 gene, MDR-associated protein-1 (MRP-1), topoisomerase (topo) I, and topo IIalpha were measured by real-time reverse transcription-polymerase chain reaction. The cutoff values of each gene were determined by the receiver operating characteristic curve. MDR-1 expression was significantly higher in patients who did not respond to TJ therapy. The expression of topo IIalpha was significantly higher in patients who did respond to EP therapy. The expression of topo I was significantly higher in patients who did respond to CPT-11/CDDP. MRP-1 expression did not differ between responders and nonresponders in all regimens. The cutoff value was 80 for MDR-1, 90 for topo IIalpha, and 200 for topo I. Next, to evaluate genetic diagnosis, 31 patients were newly added. The accuracy of this genetic diagnosis for chemosensitivity was 85.7% for TJ, 77.8% for EP, and 100.0% for CPT-11/CDDP therapy. The present study suggests that genetic diagnosis may be useful to determine chemosensitivity in patients with epithelial ovarian cancer.


Subject(s)
Antigens, Neoplasm/genetics , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , DNA Topoisomerases, Type II/genetics , DNA Topoisomerases, Type I/genetics , DNA-Binding Proteins/genetics , Multidrug Resistance-Associated Proteins/genetics , Ovarian Neoplasms/drug therapy , Ovarian Neoplasms/genetics , Adult , Aged , Antigens, Neoplasm/biosynthesis , Antigens, Neoplasm/metabolism , Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics , Camptothecin/administration & dosage , Camptothecin/analogs & derivatives , Carboplatin/administration & dosage , Cisplatin/administration & dosage , DNA Topoisomerases, Type I/biosynthesis , DNA Topoisomerases, Type I/metabolism , DNA Topoisomerases, Type II/biosynthesis , DNA Topoisomerases, Type II/metabolism , DNA-Binding Proteins/biosynthesis , DNA-Binding Proteins/metabolism , Drug Resistance, Multiple/genetics , Drug Resistance, Neoplasm/genetics , Epithelial Cells/pathology , Female , Genes, MDR , Humans , Irinotecan , Middle Aged , Multidrug Resistance-Associated Proteins/biosynthesis , Multidrug Resistance-Associated Proteins/metabolism , Ovarian Neoplasms/metabolism , Ovarian Neoplasms/pathology , Paclitaxel/administration & dosage , RNA, Messenger/biosynthesis , RNA, Messenger/genetics
4.
Oncogene ; 25(1): 79-90, 2006 Jan 05.
Article in English | MEDLINE | ID: mdl-16170361

ABSTRACT

The adenovirus type 5 gene E1A is known to suppress tumorigenicity by transcriptionally downregulating HER-2/neu (HER2) or by inducing apoptosis. We show here that E1A also suppressed the tumorigenicity of the low-HER2-expressing ovarian cancer cell line OVCAR-3 by decreasing cell proliferation. We further found that the mechanism responsible for this reduced proliferation is the presence of PEA15 (phosphoprotein enriched in astrocytes), which is upregulated by E1A in ovarian cancer; PEA15 promotes translocation of ERK from the nucleus to the cytoplasm, leading to inhibition of ERK-dependent transcription and proliferation. Indeed, siRNA-mediated knockdown of PEA15 expression in OVCAR-3 stable E1A transfectants resulted in a nuclear accumulation of the active form of ERK, followed by an increase in Elk-1 activity, DNA synthesis, and anchorage-independent growth. Finally, PEA15 by itself suppressed colony formation in breast and ovarian cancer cell lines, in which E1A is known to have antitumor activity. We conclude that part of the antitumor effect of E1A in ovarian cancer results from cytoplasmic sequestration of the activated form of ERK by PEA15.


Subject(s)
Adenovirus E1A Proteins/metabolism , Apoptosis , Cytoplasm/metabolism , Extracellular Signal-Regulated MAP Kinases/metabolism , Gene Expression Regulation, Neoplastic , Ovarian Neoplasms/drug therapy , Phosphoproteins/metabolism , Antineoplastic Agents/pharmacology , Apoptosis Regulatory Proteins , Blotting, Western , Cell Line, Tumor , Cell Nucleus/metabolism , Cell Proliferation , DNA/metabolism , Down-Regulation , Enzyme Activation , Female , Genetic Vectors/metabolism , Humans , Intracellular Signaling Peptides and Proteins , Microscopy, Fluorescence , Ovarian Neoplasms/metabolism , RNA, Small Interfering/metabolism , Receptor, ErbB-2/metabolism , Time Factors , Transcription, Genetic , Transfection , Up-Regulation
5.
Cancer Gene Ther ; 13(5): 451-9, 2006 May.
Article in English | MEDLINE | ID: mdl-16294215

ABSTRACT

Radiation-induced apoptosis is thought to underlie the toxicity of radiation to normal tissues as well as to cancer cells. We hypothesized that specific ectopic overexpression of the antiapoptotic molecule Bcl-2 in normal cells would inhibit radiation-induced apoptosis and thereby reduce radiation-induced toxicity in normal cells. To express Bcl-2 specifically in normal cells (which have wild-type (wt) p53) but not in cancer cells (which often have mutated p53), we constructed a Bcl-2 expression plasmid (PG13-Bcl-2) with a minimal promoter regulated by multiple wt p53 DNA-binding sites and found that the presence of wt p53 protein strongly upregulated Bcl-2 expression through this plasmid. Transfection of NIH 3T3 fibroblasts, which express wt p53, with PG13-Bcl-2 increased cell survival and reduced apoptosis; however, transfection of MDA-MB-231 breast cancer cells, which have mutated p53, did not affect survival and apoptosis of those cells. These results indicate that irradiation of normal cells rapidly upregulates the expression of wt p53, which binds to the p53 binding sequence of the PG13-Bcl-2 plasmid and increases the transcriptional activity of Bcl-2. Ectopic expression of Bcl-2 reduced radiation-induced apoptosis only in normal cells (not in cancer cells). Bcl-2 expression was detected in the lung from mice injected via a tail vein with LPD-PG13-Bcl-2 or LPD-CMV-Bcl-2, but did not in the lung from mice treated with DOTAP or LPD-PG13-mock. This novel approach to inhibiting radiation-induced apoptosis in normal cells may allow such cells to be protected from radiation-induced toxicity. Further preclinical in vivo studies are needed.


Subject(s)
Apoptosis , Proto-Oncogene Proteins c-bcl-2/metabolism , Radiation Injuries/prevention & control , Tumor Suppressor Protein p53/metabolism , Animals , Apoptosis/genetics , Cell Line, Tumor , Female , Gene Expression , Humans , Lung/chemistry , Lung/cytology , Lung/radiation effects , Mice , Mice, Inbred Strains , NIH 3T3 Cells , Plasmids/genetics , Promoter Regions, Genetic/genetics , Proto-Oncogene Proteins c-bcl-2/analysis , Proto-Oncogene Proteins c-bcl-2/genetics , Radiation Injuries/genetics , Radiation Injuries/metabolism , Transcriptional Activation , Tumor Suppressor Protein p53/genetics , Up-Regulation
6.
Int J Gynecol Cancer ; 15(4): 601-5, 2005.
Article in English | MEDLINE | ID: mdl-16014112

ABSTRACT

We conducted the present study to determine the outcome of patients with early ovarian cancer who underwent three courses of adjuvant chemotherapy after complete surgical staging. One hundred consecutive patients with stage I-II epithelial ovarian cancer who had undergone complete surgical staging and received three courses of platinum-based chemotherapy were entered in this study. Twenty-one patients were low risk, defined as stage IA-B, grade 1 and histologic types except for clear cell adenocarcinoma, and remaining 79 were high risk. All patients with stage IA or IB, whatever histologic type and histopathologic grade, were alive without disease. The 5-year survival rate was 89.4% for patients with stage IC and 76.2% for those with stage II. The 5-year survival rate for low- and high-risk patients was 100% and 89.4%, respectively. The survival rate for grade 1 was significantly better than that for grade 2 or 3. Multivariate analysis revealed that histologic grade was an independent prognostic factor in stage IC-II ovarian cancer. The outcome of patients with early ovarian cancer undergoing three courses of chemotherapy after complete surgical staging was favorable even in high-risk patients.


Subject(s)
Adenocarcinoma/drug therapy , Adenocarcinoma/surgery , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Ovarian Neoplasms/drug therapy , Ovarian Neoplasms/surgery , Adenocarcinoma/pathology , Adult , Aged , Carboplatin/administration & dosage , Chemotherapy, Adjuvant , Cisplatin/administration & dosage , Combined Modality Therapy , Cyclophosphamide/administration & dosage , Doxorubicin/administration & dosage , Female , Humans , Middle Aged , Ovarian Neoplasms/pathology , Paclitaxel/administration & dosage , Prognosis , Survival Analysis
7.
Int J Gynecol Cancer ; 13(1): 61-6, 2003.
Article in English | MEDLINE | ID: mdl-12631222

ABSTRACT

This multicenter collaborative study prospectively evaluated the effect of omentoplasty and omentopexy on the prevention of complications after pelvic lymphadenectomy. Sixty-four consecutive patients (42 cervical and 22 endometrial cancer) were enrolled and examined periodically for 12 months. All patients underwent simple, semiradical, or Okabayashi's radical hysterectomy and complete pelvic lymphadenectomy. The infracolic omentum was longitudinally divided in half and omentoplasty was performed so that bilateral omental flaps would reach the pelvic floor. The omental flaps were inserted into the retroperitoneal space and the edges of the flaps were sutured to the psoas muscle. The omental flap was then covered by the peritoneum. Incidence of lymphocele, lymphedema, and severe complications associated with lymphocele, such as infection or urinary stenosis, was evaluated at intervals for at least one year after surgery. Among the 64 patients, 12 patients received pelvic radiation because of occult lymph node metastasis. Planned omentoplasty was not possible in one patient because her omentum was too small; therefore, only unilateral omentopexy was performed. Asymptomatic lymphoceles only were detected by ultrasonogram in 12 patients (18.8%). Three patients (4.7%) had a symptomatic but pressure-only lymphocele. Hydronephrosis and bladder compression probably due to lymphocele were observed in one patient, respectively (3.1%), but resolved within 6 months. Lymphedema was observed in seven patients (10.9%) and persisted for more than 6 months in two patients (3.1%). We conclude that this simple technique of omentoplasty and omentopexy appeared to be effective in reducing the incidence of complications after pelvic lymphadenectomy.


Subject(s)
Endometrial Neoplasms/surgery , Gynecologic Surgical Procedures/methods , Lymph Node Excision/methods , Omentum/surgery , Postoperative Complications/prevention & control , Uterine Cervical Neoplasms/surgery , Adult , Aged , Female , Gynecologic Surgical Procedures/adverse effects , Humans , Hysterectomy/methods , Lymph Node Excision/adverse effects , Middle Aged , Pelvis , Postoperative Complications/etiology , Prospective Studies , Risk Factors
8.
Ann Oncol ; 14(2): 214-9, 2003 Feb.
Article in English | MEDLINE | ID: mdl-12562647

ABSTRACT

OBJECTIVES: To determine whether and how apoptosis through the p53-Bax pathway affects sensitivity to chemotherapy in cervical cancer. MATERIALS AND METHODS: Thirty patients with cervical squamous cell carcinoma, who had human papilloma virus (HPV) and underwent neoadjuvant chemotherapy, were entered in the present study. Tumor specimens were obtained before and after chemotherapy. HPV was detected by polymerase chain reaction. The expression of Ki-67, p53, Bax and Bcl-2 proteins was determined by immunohistochemical staining. Apoptotic cells were identified by the terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate biotin nick-end labeling method. RESULTS: Of 30 patients, 18 responded to chemotherapy and 12 did not. The apoptotic index in tumors of responders was significantly higher than in non-responders after chemotherapy. The Ki-67 labeling index (LI) in responders was significantly higher than in non-responders before chemotherapy. Patients with tumors >33% of the LI, which was determined by a receiver operating characteristic curve, had a better survival rate. The incidence of p53 protein expression did not differ between responders and non-responders. After chemotherapy, the expression of Bax protein in responders was more frequent and Bcl-2 protein expression was less frequent than in non-responders. CONCLUSIONS: Chemosensitivity in cervical cancer may be associated with apoptosis via the p53-Bax pathway.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Apoptosis/drug effects , Apoptosis/genetics , Carcinoma, Squamous Cell/genetics , Carcinoma, Squamous Cell/physiopathology , Genes, p53 , Proto-Oncogene Proteins/biosynthesis , Uterine Cervical Neoplasms/genetics , Uterine Cervical Neoplasms/physiopathology , Adult , Aged , Carcinoma, Squamous Cell/drug therapy , Female , Humans , Immunohistochemistry , Ki-67 Antigen/analysis , Ki-67 Antigen/biosynthesis , Middle Aged , Neoadjuvant Therapy , Papillomaviridae , Papillomavirus Infections/complications , Polymerase Chain Reaction , Predictive Value of Tests , Proto-Oncogene Proteins/analysis , Proto-Oncogene Proteins c-bcl-2/biosynthesis , Tumor Suppressor Protein p53/analysis , Tumor Suppressor Protein p53/biosynthesis , Tumor Virus Infections/complications , Uterine Cervical Neoplasms/drug therapy , bcl-2-Associated X Protein
9.
Br J Cancer ; 84(11): 1551-5, 2001 Jun 01.
Article in English | MEDLINE | ID: mdl-11384107

ABSTRACT

We conducted the present study to determine the relationship between p53-dependent apoptosis and telomerase activity in ovarian cancer cells. A human ovarian adenocarcinoma cell line, SK-OV-3 that had homozygous deletion of the p53 gene was used in this study. Wild-type p53 genes were transducted to SK-OV-3 cells with a recombinant adenovirus that contained a wild-type p53 gene (AxCAp53). IC(50)to cisplatin (CDDP) was 12.9 microM for SK-OV-3 cells and 9.2 microM for p53 gene-transducted SK-OV-3 cells. The apoptotic index for cells with p53 gene transduction was significantly higher than cells without transduction. Additionally, p53 gene transduction significantly enhanced CDDP-induced apoptosis. Bax protein in SK-OV-3 cells did not differ before and after exposure to CDDP. In SK-OV-3 cells with transduction of the p53 gene, the expression of p53 and Bax proteins increased after exposure to CDDP. Expression of Bcl-xL decreased after exposure to CDDP in SK-OV-3 cells with and without transduction. The telomerase activity in SK-OV-3 cells with the p53 gene was significantly lower compared with the cells without the p53 gene. CDDP exposure did not affect telomerase activity and human telomerase reverse transcriptase (hTERT) expression in both cell lines. We suggest that the p53 gene may relate to telomerase activity, but that p53-dependent apoptosis does not affect the activity.


Subject(s)
Adenocarcinoma/pathology , Apoptosis , Gene Expression Regulation, Neoplastic , Genes, p53/genetics , Ovarian Neoplasms/pathology , RNA , Telomerase/metabolism , Adenocarcinoma/enzymology , Adenocarcinoma/genetics , DNA-Binding Proteins , Female , Humans , Ovarian Neoplasms/enzymology , Ovarian Neoplasms/genetics , Tumor Cells, Cultured
10.
Clin Cancer Res ; 7(4): 892-5, 2001 Apr.
Article in English | MEDLINE | ID: mdl-11309338

ABSTRACT

The tumor suppressor PTEN acts as a lipid phosphatase, regulates the phosphatidylinositol 3-kinase (PI3K)/Akt-signaling pathway, and modulates cell cycle progression and cell survival. Somatic mutations of PTEN have been reported in a variety of cancers, especially in endometrial carcinoma. To clarify whether and how PTEN and the PI3K/Akt pathway relates to endometrial carcinoma, we examined the expression of those pathway-related proteins in patients with endometrial carcinoma. Of 103 endometrial carcinomas, 37 (36%) showed negative immunohistochemical staining of PTEN. Western blotting revealed that the expression of PTEN in PTEN-negative cases was significantly lower compared with that in positive cases. In contrast, phospho-Akt level in negative cases was significantly higher. We found a significant inverse correlation between PTEN and phospho-Akt (r = -0.796). The expression of phospho-Bad was greater in negative cases, suggesting that Bad might be a target for AKT: The present study demonstrates the phosphorylation of Akt accompanied by the loss of PTEN in clinical specimens of endometrial carcinomas.


Subject(s)
Endometrial Neoplasms/metabolism , Phosphoric Monoester Hydrolases/genetics , Protein Serine-Threonine Kinases , Proto-Oncogene Proteins/metabolism , Tumor Suppressor Proteins , Carrier Proteins/metabolism , Endometrial Neoplasms/enzymology , Endometrial Neoplasms/genetics , Female , Gene Silencing , Humans , Immunohistochemistry , PTEN Phosphohydrolase , Phosphatidylinositol 3-Kinases/metabolism , Phosphorylation , Proto-Oncogene Proteins c-akt , Statistics as Topic , bcl-Associated Death Protein
11.
Hum Cell ; 14(3): 165-71, 2001 Sep.
Article in English | MEDLINE | ID: mdl-11774736

ABSTRACT

Recent studies suggest that drug induced apoptosis relates to the sensitivity. p53 gene, which has a pivotal role in inducing apoptosis, frequently mutates in ovarian cancer. Therefore, p53 gene status and chemosensitivity in epithelial ovarian cancer is discussed. Nonresponders to chemotherapy had mutations of the p53 gene more frequently (83% for nonresponders vs. 16% for responders) in patients with epithelial ovarian cancer undergoing platinum-base chemotherapy. Apoptotic index was significantly greater in tumors with wild-type p53 gene than those without the gene. p53 gene transduction markedly enhanced the sensitivity to cisplatin (CDDP) and CDDP-induced apoptosis, but did not affect the sensitivity to paclitaxel (PTX) nor PTX-induced apoptosis in ovarian cancer cells without p53 gene. The combination treatment with a recombinant adenovirus carrying a wild-type p53 gene (AxCAp53) and CDDP significantly suppressed tumor growth of ovarian cancer cells with and without p53 gene, compared with a single treatment of either AxCAp53 or CDDP in ovarian cancer xenograft. Apoptotic index was significantly higher and proliferating cell nuclear antigen labeling index was relatively lower in an ovarian cancer xenograft without p53 gene receiving combination treatment, compared with a single treatment of either CDDP or AxCAp53, suggesting that the transduction of p53 gene induces apoptosis, but does not enhance the DNA repair system. A significant survival advantage was observed in the combination treatment compared with other treatments in carcinoma peritonitis models. In conclusion, p53 gene status contributes the sensitivity to CDDP in ovarian cancer. Additionally, combination treatment of p53 gene transduction and CDDP may be an effective therapeutic modality for ovarian cancer without wild-type p53 gene.


Subject(s)
Adenocarcinoma/genetics , Genes, p53/genetics , Ovarian Neoplasms/genetics , Adenocarcinoma/pathology , Adenocarcinoma/therapy , Animals , Apoptosis/drug effects , Apoptosis/genetics , Cisplatin/pharmacology , Cisplatin/therapeutic use , Combined Modality Therapy , Drug Resistance, Neoplasm , Female , Genetic Therapy , Humans , Mutation , Ovarian Neoplasms/pathology , Ovarian Neoplasms/therapy , Paclitaxel/pharmacology , Paclitaxel/therapeutic use , Transduction, Genetic , Tumor Cells, Cultured
12.
Hum Cell ; 14(3): 237-43, 2001 Sep.
Article in English | MEDLINE | ID: mdl-11774743

ABSTRACT

We discussed the role of DNA topoisomerase I (topo I) inhibitor, which is now widely used in clinical practice, in cisplatin-resistant ovarian cancer. Our study showed the synergistic actions between cisplatin and 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of 7-ethyl-10-[4-(1-pyperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11), in two cisplatin-resistant cancer cell lines, HeLa/CDDP and KFr cells, but not in each parent cell line, HeLa and KF cells. Furthermore, HeLa/CDDP cells had a collateral sensitivity to SN-38. The levels of topo I protein in the cisplatin-resistant cells did not differ from those of their parent cell lines and were unaffected by exposure to cisplatin. In contrast, topo I enzymatic activity was 2-4 fold higher in the cisplatin-resistant cell lines compared with their respective parent cell lines. A significant correlation between the sensitivity for SN-38 and topo I activity human clear cell carcinoma cell lines, which are known as intrinsically ciasplatin-resistant cancer, was observed. Next, we examined the relationship between topo I activity and sensitivity to second-line chemotherapy consisting of cisplatin and CPT-11. A total of 30 patients with ovarian cancer who had initially undergone chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide (CAP) and exhibited measurable lesions were entered in the study. Tumor samples were obtained in the period between the initial and the second-line chemotherapy. Of those 30 patients, 18 responded to second-line chemotherapy and 12 did not. Topo I activity in tumor samples of responder was significantly greater than that of in nonresponders. In 8 cases whose samples could be obtained before and after CAP, topo I activity significantly increased after CAP therapy. Consequently, the combination therapy with cisplatin and CPT-11 may be effective for patients with cisplatin-resistant ovarian cancer. In addition, topo I enzymatic activity may be a predictor of the sensitivity for topo I inhibitor.


Subject(s)
Camptothecin , Camptothecin/analogs & derivatives , Cisplatin , Drug Resistance, Neoplasm , Enzyme Inhibitors , Ovarian Neoplasms/drug therapy , Topoisomerase I Inhibitors , Animals , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Camptothecin/administration & dosage , Camptothecin/pharmacology , Cisplatin/administration & dosage , Cisplatin/pharmacology , DNA Topoisomerases, Type I/metabolism , Drug Synergism , Enzyme Inhibitors/administration & dosage , Female , HeLa Cells , Humans , Irinotecan , Ovarian Neoplasms/enzymology , Ovarian Neoplasms/pathology , Tumor Cells, Cultured
13.
Oncology ; 59(4): 329-35, 2000 Nov.
Article in English | MEDLINE | ID: mdl-11096346

ABSTRACT

OBJECTIVE: The aim of this study was to evaluate the combination effect of paclitaxel (PTX) and cisplatin (CDDP) and to determine the mechanisms of interaction between these agents. METHODS AND RESULTS: We used human ovarian adenocarcinoma cell lines, namely a parent cell line (KF), a CDDP-resistant cell line (KFr) and a PTX-resistant cell line (KFTx).The combination effect of PTX and CDDP was synergistic on KF and KFTx and additive on KFr. The incidence of anaphase or telophase, evaluated by immunofluorescence microscopy, decreased with PTX and significantly decreased with PTX and CDDP in KF and KFTx. The concentration of PTX, which was measured by high-performance liquid chromatography, was higher in KF and KFTx cells treated with a combination of PTX and CDDP than those treated with PTX alone. Multidrug resistance gene mRNA appeared in KFTx and its expression decreased after exposure to PTX and CDDP. After exposure to CDDP, the expression of multidrug resistance-associated protein (MRP) and the concentration of glutathione increased in KF, but not in KFr or KFTx. MRP expression slightly increased in KF and KFTx after exposure to PTX. In contrast, its expression decreased in KFr. CONCLUSION: The present study suggests that CDDP enhances PTX accumulation and that the interaction of these agents is synergistic in CDDP-sensitive cells.


Subject(s)
Adenocarcinoma/drug therapy , Adenocarcinoma/metabolism , Antineoplastic Combined Chemotherapy Protocols/metabolism , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Ovarian Neoplasms/drug therapy , Ovarian Neoplasms/metabolism , Anaphase/drug effects , Antineoplastic Agents, Phytogenic/metabolism , Antineoplastic Agents, Phytogenic/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/pharmacology , Cisplatin/metabolism , Cisplatin/therapeutic use , DNA Primers , DNA, Complementary/analysis , DNA, Neoplasm/analysis , Down-Regulation/drug effects , Drug Resistance, Multiple/genetics , Drug Resistance, Neoplasm/genetics , Drug Synergism , Female , Gene Expression Regulation, Neoplastic/drug effects , Humans , Mitosis/drug effects , Paclitaxel/metabolism , Paclitaxel/therapeutic use , Polymerase Chain Reaction , Telophase/drug effects , Tumor Cells, Cultured
14.
Eur J Surg Oncol ; 26(5): 464-7, 2000 Aug.
Article in English | MEDLINE | ID: mdl-11016467

ABSTRACT

AIMS: The aim of the present study was to evaluate the outcome of patients with stage lb-IIb cervical adenocarcinoma treated with radical hysterectomy, and to determine the clinicopathological characteristics of those patients. METHODS: A total of 255 patients with cervical carcinoma stage Ib-IIb (57 adenocarcinoma and 198 squamous cell carcinoma) who had undergone radical hysterectomy were included in this study. Patient survival distribution was calculated using the Kaplan-Meier method. RESULTS: The estimated 5-year survival rate for patients with adenocarcinoma was significantly poorer than that for patients with squamous cell carcinoma (77.9% vs 91.7%). The survival rate in stage Ib patients did not differ between two groups (95.8% vs 94.4% respectively). The incidence of lymph node involvement was significantly higher in patients with adenocarcinoma than in those with squamous cell carcinoma (31.6% vs 14.8%). Among patients receiving post-operative radiotherapy, the survival rate for adenocarcinoma (71.1%) was significantly poorer than that for squamous cell carcinoma (90.0%). When patients underwent radical hysterectomy, the survival rate for stage II patients with adenocarcinoma was significantly poorer than that for patients with squamous cell carcinoma. CONCLUSIONS: The higher incidence of lymph node involvement and lower response to post-operative radiotherapy are considered to be factors of poorer prognosis in cervical adenocarcinoma.


Subject(s)
Adenocarcinoma/pathology , Carcinoma, Squamous Cell/pathology , Hysterectomy , Uterine Cervical Neoplasms/pathology , Adenocarcinoma/mortality , Adenocarcinoma/surgery , Adult , Aged , Carcinoma, Squamous Cell/mortality , Carcinoma, Squamous Cell/surgery , Female , Humans , Hysterectomy/methods , Lymphatic Metastasis , Medical Records , Middle Aged , Neoplasm Staging , Prognosis , Proportional Hazards Models , Retrospective Studies , Survival Analysis , Uterine Cervical Neoplasms/mortality , Uterine Cervical Neoplasms/surgery
15.
Eur J Cancer ; 36(14): 1863-8, 2000 Sep.
Article in English | MEDLINE | ID: mdl-10974635

ABSTRACT

We conducted this study to determine whether the sensitivity of ovarian cancer cells to paclitaxel (PTX) relates to cells undergoing p53-dependent apoptosis. Human ovarian adenocarcinoma cell lines (SK-OV-3, KF and KP cells) were used in this study. In SK-OV-3 and KP cells, which have a homozygous deletion of the TP53 gene, wild-type TP53 gene-transduction markedly enhanced the sensitivity to cisplatin (CDDP), but did not enhance the sensitivity to PTX. In all cells, the apoptotic index was increased by CDDP or PTX. After exposure to CDDP, p53 and Bax protein expression increased and Bcl-xL expression decreased in the KF cells and TP53 gene-transducted SK-OV-3 cells. However, these proteins did not change in KP cells. Therefore, the role of p53 in CDDP-induced apoptosis depends upon the cell type. In contrast, TP53 gene status did not correlate with PTX-induced cytotoxicity in any of the cell lines with differing apoptotic pathways. In conclusion, the sensitivity to PTX may not be related to p53-dependent apoptosis in ovarian cancer cells.


Subject(s)
Antineoplastic Agents/therapeutic use , Apoptosis/genetics , Genes, p53/genetics , Ovarian Neoplasms/drug therapy , Paclitaxel/therapeutic use , Proto-Oncogene Proteins c-bcl-2 , Antineoplastic Agents, Phytogenic/therapeutic use , Cisplatin/therapeutic use , Dose-Response Relationship, Drug , Female , Humans , Ovarian Neoplasms/genetics , Ovarian Neoplasms/pathology , Proto-Oncogene Proteins/genetics , Tumor Cells, Cultured , bcl-2-Associated X Protein
16.
Eur J Cancer ; 36(14): 1869-75, 2000 Sep.
Article in English | MEDLINE | ID: mdl-10974636

ABSTRACT

To clarify the effect of a combination treatment consisting of a recombinant adenovirus carrying a wild-type TP53 gene (AxCATP53) and cisplatin (CDDP), we examined p53-dependent apoptosis in ovarian cancer xenografts with and without the wild-type TP53 gene. Severe combined immunodeficiency (SCID) mice were implanted with ovarian cancer cell lines consisting of SK-OV-3 cells without the TP53 gene and KF cells with the TP53 gene. In SK-OV-3 and KF tumours, the inhibitory effect of the combination treatment on tumour growth was significant, compared with a single treatment with CDDP alone or AxCATP53 alone. The apoptotic index increased significantly after combination treatment in the SK-OV-3 tumours. The expression of Bax protein in SK-OV-3 tumours was weak, but strengthened after TP53 gene transfection. In contrast, AxCATP53 transfection did not affect CDDP-induced apoptosis in the KF tumours. Therefore, combination treatment of AxCATP53 and CDDP may be a new strategy for treating ovarian cancer with or without the TP53 gene.


Subject(s)
Antineoplastic Agents/therapeutic use , Cisplatin/therapeutic use , Genes, p53/genetics , Ovarian Neoplasms/therapy , Proto-Oncogene Proteins c-bcl-2 , Transfection/methods , Transformation, Genetic , Animals , Female , Humans , Mice , Mice, SCID , Neoplasm Transplantation , Ovarian Neoplasms/genetics , Proto-Oncogene Proteins/genetics , Transplantation, Heterologous , Tumor Cells, Cultured , bcl-2-Associated X Protein
17.
Gynecol Obstet Invest ; 49(3): 204-8, 2000.
Article in English | MEDLINE | ID: mdl-10729763

ABSTRACT

To elucidate the relationship between telomerase activity and chemosensitivity in epithelial ovarian cancer, telomerase activity and telomere length (TRF) were examined before and after chemotherapy. Of 21 patients, 9 patients responded to chemotherapy and 12 did not. The positivity of telomerase activity did not significantly differ between responders and nonresponders. There were no differences in the mean length and the distribution of TRF between the two groups. Those distributions became narrow after chemotherapy in both groups. Seven nonresponders (58.3%) exhibited an increase in telomerase activity after chemotherapy but none of the responders showed an increase in activity. Telomerase activity may relate to chemosensitivity in epithelial ovarian cancer.


Subject(s)
Ovarian Neoplasms/drug therapy , Ovarian Neoplasms/enzymology , Telomerase/analysis , Aged , Female , Humans , Middle Aged , Ovarian Neoplasms/ultrastructure , Telomere/ultrastructure
18.
Jpn J Cancer Res ; 90(12): 1373-9, 1999 Dec.
Article in English | MEDLINE | ID: mdl-10665656

ABSTRACT

Since HeLa cells possess very little functional p53 activity, they could be originally resistant to genotoxic stress-induced apoptosis. Therefore, it is likely that the drug-resistant cells derived from HeLa cells are more resistant to apoptosis. The aim of this study was to determine whether cisplatin-resistant cells derived from HeLa cells have an apoptosis-resistant phenotype. A cisplatin-resistant cell subline, HeLa/CDDP cells, showed a 19-fold resistance to cisplatin compared with the parent cells. The subline showed a collateral sensitivity to paclitaxel. An equitoxic dose (IC50) of cisplatin produced DNA fragmentation in HeLa cells but not in HeLa/CDDP cells. Transfection of wild-type p53 gene enhanced the cytotoxicity of cisplatin and cisplatin-induced apoptosis in HeLa cells but not in HeLa/CDDP cells, although it caused p53 overexpression in both cell lines. The expression of caspase 1 (interleukin-1beta-converting enzyme, ICE) mRNA and the overexpression of bax protein were observed only in HeLa cells. Paclitaxel-induced DNA fragmentation appeared less in HeLa/CDDP cells than in HeLa cells. p53 gene transfection did not affect the extent of DNA fragmentation in either cell line, suggesting that paclitaxel may induce p53-independent apoptosis. These findings suggest that HeLa/CDDP cells may have an acquired phenotype that is resistant to p53-dependent and -independent apoptosis.


Subject(s)
Antineoplastic Agents/pharmacology , Apoptosis/drug effects , Cisplatin/pharmacology , HeLa Cells/drug effects , Signal Transduction/drug effects , Tumor Suppressor Protein p53/physiology , Antineoplastic Agents, Phytogenic/pharmacology , Drug Resistance, Neoplasm , Drug Screening Assays, Antitumor , Humans , Paclitaxel/pharmacology , Phenotype , Tumor Suppressor Protein p53/genetics
19.
Oncology ; 55(6): 517-20, 1998.
Article in English | MEDLINE | ID: mdl-9778616

ABSTRACT

The objective of this study was to evaluate the incidence of residual disease and the presence of human papillomavirus (HPV) after conization. Data on 53 patients with carcinoma in situ or microinvasive carcinoma who underwent hysterectomy less than 2 months after conization were examined. Seven of 53 patients (13%) had positive margins. In 4 of these 7 patients (57%), residual disease was found in the postconization hysterectomy specimen. Two of 46 patients (4%) with negative margins also had residual disease. HPV DNA was detected by PCR in 27 of 53 conization specimens and in 2 postconization hysterectomy specimens. Of 2 patients, 1 did not have residual disease. Residual disease could be present even with a negative conization margin, and HPV DNA may be found in a histologically normal cervix after conization.


Subject(s)
Carcinoma in Situ/surgery , Carcinoma in Situ/virology , Conization , DNA, Viral/analysis , Neoplasm, Residual/virology , Papillomaviridae/genetics , Papillomavirus Infections/genetics , Tumor Virus Infections/genetics , Uterine Cervical Neoplasms/surgery , Uterine Cervical Neoplasms/virology , Adult , Aged , Carcinoma in Situ/pathology , Female , Humans , Hysterectomy , Middle Aged , Papillomavirus Infections/complications , Papillomavirus Infections/virology , Polymerase Chain Reaction , Tumor Virus Infections/complications , Tumor Virus Infections/virology , Uterine Cervical Neoplasms/pathology
20.
Cancer ; 82(4): 697-702, 1998 Feb 15.
Article in English | MEDLINE | ID: mdl-9477102

ABSTRACT

BACKGROUND: No useful predictor of resistance or sensitivity to second-line chemotherapy is known for ovarian cancer. The objective of this prospective study was to determine the utility of tumor glutathione S-transferase-pi (GST-pi) expression or glutathione (GSH) concentration in predicting ovarian cancer patients' responses to second-line chemotherapy. METHODS: Tumor samples were obtained from 26 patients with relapsed epithelial ovarian cancer 3-4 weeks before the initiation of second-line chemotherapy with etoposide (daily on Days 1-5) and cisplatin (on Day 5). The expression of GST-pi in tumor samples was determined by immunohistochemical staining and Western blot analysis. GSH concentration was measured by an enzymatic assay. RESULTS: The response rate was 38.4%. The estimated 3-year survival rate for the responders (66.7%) significantly exceeded that for the nonresponders (9.1%). Expression of GST-pi by immunohistochemical staining was more frequently observed in nonresponders (2 of 10 responders vs. 11 of 16 nonresponders). Western blot analysis detected GST-pi in all cases. There was no significant difference in the relative density values of the GST-pi Western blot analysis between the two groups. The mean value of GSH concentration in nonresponders was significantly higher than in responders (18.4 +/- 9.7 vs. 7.5 +/- 8.2 microg/mg protein). GSH concentration was below the cutoff point (10.3 microg/mg protein) in all responders except one. CONCLUSIONS: Second-line chemotherapy consisting of etoposide and cisplatin is effective in the treatment of relapsed epithelial ovarian cancer. In addition, tumor concentration of GSH may be a useful predictor of the response to this therapy.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Cystadenocarcinoma, Mucinous/drug therapy , Cystadenocarcinoma, Serous/drug therapy , Glutathione/metabolism , Ovarian Neoplasms/drug therapy , Adult , Aged , Biomarkers, Tumor/metabolism , Blotting, Western , Cisplatin/therapeutic use , Cystadenocarcinoma, Mucinous/metabolism , Cystadenocarcinoma, Mucinous/pathology , Cystadenocarcinoma, Serous/metabolism , Cystadenocarcinoma, Serous/pathology , Drug Resistance, Neoplasm , Etoposide/therapeutic use , Female , Glutathione S-Transferase pi , Glutathione Transferase/metabolism , Humans , Isoenzymes/metabolism , Middle Aged , Neoplasm Recurrence, Local/drug therapy , Ovarian Neoplasms/metabolism , Ovarian Neoplasms/pathology , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...